Cisbio and Lumiphore Announce Partnership for new Product and Technology Development
News Sep 11, 2007
Under the agreement, Cisbio holds the exclusive rights to apply Lumi4™ technology to current and future research and development initiatives in TR-FRET-based (Time-Resolved Fluorescence Resonance Energy Transfer) assays for drug discovery.
Lumi4™ compounds bring photophysical properties, increased sensitivity and stability to TR-FRET assays for high-throughput screening (HTS) applications and the growing homogeneous assay market.
The incorporation of Lumi4™ compounds to Cisbio’s proprietary HTRF® technology has the potential to enable the development of a second generation of assay platforms used in HTS, particularly in the fields of GPCR (G-Protein Coupled Receptors) and kinase screening.
Combining the two technologies will allow for the development of new HTRF® applications and increased possibilities for HTS implementation of Cisbio’s assays.
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019